| Revenue Growth | Americas grew 35% to $3.8M; EMEA grew 14% to $4.1M. |
|---|---|
| Mgmt Confidence | Confident in 2027 EBITDA neutrality through controlled expenses and top-line growth. |
| Demand Visibility | Strong customer demand noted; currently limited by silicon wafer supply constraints. |
| Order Book | Backlog exists due to supply constraints; expect to clear by year-end. |
| Margin Trends | Adjusted gross margin improved to 48% from 46% year-over-year. |
| Op. Leverage | Operating expenses decreased 12% to $10.5M; adjusted OpEx down 9%. |
| Vol vs Price | Volume-led growth with record 9,870 flow cells sold, up 18%. |
| Segment Growth | Consumables up 24%; Instruments/Services up 24%; Software down 31%. |
| New Clients | University of Rochester and Memorial Sloan Kettering launched OGM-based testing. |
| Capex & Debt | Ended quarter with $8.7M in cash and equivalents. |
| Regulatory | Proposed Moldex LCD for Medicare coverage in 31 US states. |
| Commentary | Shifted from aggressive installed base growth to profitable routine-use utilization. |
Growth
Revenue grew 12% to $8.3M; consumables up 24% to $4.7M; flow cells up 18%.
Outlook
Reiterated 2026 revenue of $31M-$33M; targeting EBITDA neutrality by end of 2027.
Risks
Management used vague language regarding specific 2027 revenue drivers and Sloan Kettering implementation details.
The company's earnings call, NASDAQ: BNGO, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Bionano Genomics, Inc.: key numbers
- Share price
- $0.9400Close, Nov 16
- Market cap
- $13.1M
- Shares outstanding
- 13.99MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Bionano Genomics, Inc.
All →Bionano Genomics Q3 2026 Results: Net Loss of $6.45M, Loss Narrows
Bionano Genomics reported total revenue of $8.28 million for the third quarter of 2026, a 12% increase year-over-year, while narrowing its quarterly net loss to $6.45 million compared to $8.50 million in 2025. The company's cash position remains tight, with total cash, cash equivalents, and investments decreasing significantly from $19.27 million at the end of 2025 to $8.17 million as of September 30, 2026.
- Key figure
- Net loss $6.45M
Bionano Genomics Financial Results
Bionano Genomics reported Q3 2026 revenue of $8.3 million, a 12% increase year-over-year, driven by a 24% rise in consumables revenue. The company reiterated its full-year 2026 revenue guidance of $31 million to $33 million and highlighted progress in the clinical adoption of its optical genome mapping (OGM) technology.
- Term
- Q3 2026
“Our third quarter results reflect the momentum building across our business and the broader genomics community, further accelerating the adoption of optical genome mapping (OGM) in clinical and commercial settings.”
Al Luderer, Ph.D., chairman and interim chief executive officer
“Coverage and regulatory progress this quarter helped build a clearer reimbursement pathway for OGM-based testing, which we expect to support broader clinical adoption over time.”
Al Luderer, Ph.D., chairman and interim chief executive officer
Bionano Genomics Investor Presentation
Bionano Genomics Chairman and Interim CEO Al Luderer is presenting at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company filed its conference presentation deck as an exhibit, which includes updates on its business strategy, optical genome mapping (OGM) adoption, and cost-saving initiatives. The presentation also addresses the company's focus on extending its cash runway and reaching a pathway to profitability.
- Counterparty
- H.C. Wainwright